Rédaction Africa Links 24 with Casey Ross
Published on 2024-02-07 09:30:37
David Reese believes that the merging of biotech and big tech to combat human disease with artificial intelligence represents a pivotal moment in the field. As the head of drug research and development at Amgen, Reese has been at the forefront of this shift and was recently appointed as the company’s first chief technology officer. According to Reese, this move towards integrating AI into the drug discovery process is not just a trend, but a necessity as the technology continues to rapidly advance.
In a recent interview, Reese emphasized the significant improvements in AI models that are occurring every six months, citing a 10-fold increase in their effectiveness. As a medical oncologist, Reese understands the potential impact that AI can have on drug discovery and believes that it is essential for companies like Amgen to invest in this technology in order to make practical and pragmatic advancements in the field.
The integration of AI into the drug discovery process represents a significant shift in the biotech industry. Traditionally, drug discovery has been a lengthy and costly process, with many potential compounds failing in the later stages of development. By leveraging AI to analyze vast amounts of data and identify potential drug targets, companies like Amgen hope to streamline the process and increase the likelihood of success.
The use of AI in drug discovery is not limited to just identifying potential drug targets. It can also be used to optimize clinical trial designs, predict patient responses to treatments, and identify new therapeutic uses for existing drugs. These applications have the potential to revolutionize the way drugs are discovered, developed, and brought to market.
Amgen is not the only company investing heavily in AI for drug discovery. Across the industry, there has been a significant increase in the use of AI and machine learning to accelerate the development of new therapeutics. This has led to the creation of new roles within biotech companies, such as chief technology officers, and a growing demand for individuals with expertise in both biotech and AI.
The future of drug discovery and development is increasingly being shaped by the integration of AI and big tech into the biotech industry. As AI continues to advance at a rapid pace, companies like Amgen are recognizing the need to invest in this technology in order to remain competitive and continue making meaningful advancements in the field.
In conclusion, the merging of biotech and big tech to combat human disease with artificial intelligence represents a significant turning point in the industry. Companies like Amgen are at the forefront of this shift, recognizing the need to integrate AI into the drug discovery process in order to stay ahead of the curve. As AI continues to rapidly advance, the impact on drug discovery and development is likely to be profound, revolutionizing the way new therapeutics are discovered, developed, and brought to market.
